Nan ChenNan ChenAffiliations

Feb 8, 2024 | thelancet.com | Nan Chen |Rita Nanda |Nan ChenNan ChenAffiliations

Enobosarm has anti-tumour activity in patients with ER-positive, HER2-negative advanced breast cancer, showing that AR activation can result in clinical benefit, supporting further clinical investigation of selective AR activation strategies for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer.